L-Ergothioneine for Dietary Supplements
The "longevity vitamin" — FDA GRAS, EU Novel Food authorized
For supplement brands and formulators developing longevity, cognitive health, and antioxidant products
Your Challenge. Our Answer.
We understand the specific problems you face — and we built solutions for each one.
The Problem
Consumer demand for science-backed longevity ingredients is growing, but most antioxidants have undifferentiated positioning
Mironova’s Answer
L-Ergothioneine has a dedicated transporter (OCTN1) — it’s actively accumulated in tissues, unlike passively absorbed antioxidants. The “longevity vitamin” positioning is peer-reviewed.
The Problem
Regulatory pathway for novel ingredients is complex — brands need ingredients with established safety dossiers
Mironova’s Answer
EGT has FDA GRAS status (GRN 000734) and EU Novel Food authorization (EFSA, up to 30 mg/day). Clear regulatory pathway.
The Problem
Dietary intake of EGT is very low in Western diets (mushrooms are the primary source), creating a supplementation opportunity
Mironova’s Answer
Estimated US dietary intake is far below levels associated with benefit in epidemiological studies — strong rationale for supplementation
Published Evidence
Key findings from peer-reviewed literature relevant to your application.
Reduced Mortality & CV Risk
Prospective study (n = 3,236): higher plasma EGT independently associated with reduced all-cause mortality and lower cardiovascular events.
Smith et al., Heart 2020
"Longevity Vitamin" Hypothesis
EGT proposed as a “longevity vitamin” — insufficient dietary EGT may accelerate aging-associated damage.
Ames, PNAS 2018
Cognitive Decline Association
Plasma EGT levels decline significantly beyond age 60 and are lower in individuals with mild cognitive impairment.
Cheah et al., Biochem. Biophys. Res. Commun. 2016
Longitudinal Cognitive Cohort
In 470 memory clinic participants followed up to 5 years, lower baseline plasma EGT was associated with faster cognitive decline across multiple domains.
Cheah et al., Free Radic. Biol. Med. 2022
16-Week RCT in Older Adults
RCT (n=147, ages 55–79) testing 10 and 25 mg daily EGT. Clear dose-dependent pharmacokinetics. Signals in subjective memory and sleep initiation at 25 mg. No adverse events.
Halliwell, Cheah et al., Clinical Nutrition 2024
FDA GRAS Status
FDA issued “no questions” response to GRAS conclusion for L-Ergothioneine (GRN 000734).
US FDA GRAS Database, 2018
Recommended Products
The specific products from our catalog that match your application.
Supplement Formulation Notes
- Recommended dose: up to 30 mg/day (EU authorized level)
- Compatible with capsule, tablet, and powder formats
- Stable under standard supplement storage conditions
- Synergistic potential with vitamin C and other antioxidants
Request Technical Data
Get product specifications, CoA samples, and pricing for your evaluation.
Request Ingredient Samples
Receive evaluation-grade L-Ergothioneine with technical data sheet and regulatory documentation.
Or call us at +1 (973) 244-0393
Related Resources
Technical data, product specifications, and application guidance.